OR WAIT null SECS
Sanofi will perform the fill/finish of up to 200 million doses of Moderna’s COVID-19 vaccine at its Ridgefield, NJ, facility starting in September 2021.
Sanofi announced on April 26, 2021 that it has entered into an agreement with Moderna to aid in the manufacture of Moderna’s COVID-19 vaccine.
According to a company press release, Sanofi will perform the fill/finish of up to 200 million doses of the vaccine at its Ridgefield, NJ, facility starting in September 2021.
Sanofi has also provided manufacturing support to BioNTech for 125 million doses of its COVID-19 vaccine for the European Union and Johnson & Johnson for 12 million doses per month of its single-shot COVID-19 vaccine, Sanofi said in the press release. Additionally, the company continues to develop its own COVID-19 vaccine programs using the same recombinant protein-based manufacturing technology as one of its seasonal influenza vaccines, combined with GlaxSmihKline’s pandemic adjuvant platform.
“Since the beginning of the pandemic, we have been mobilizing on multiple fronts and we showed solidarity across the industry,” said Paul Hudson, CEO, Sanofi, in the press release. “We are one of the few pharmaceutical companies to leverage many industrial partnerships to improve global supply and access to COVID-19 vaccines, while in parallel, also continuing to develop our two COVID-19 vaccine programs.”